Shopping Cart
Remove All
Your shopping cart is currently empty
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | - | In Stock | |
| 5 mg | $745 | In Stock | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,780 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
| Description | Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody targeting the p19 subunit of IL-23 with a Kd value of 136 pM, useful for studying psoriasis. |
| Targets&IC50 | HeLa cells:23 pM |
| In vitro | Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressing human IL-23Rα and IL-12Rβ1 receptors, with an IC50 of 23 pM[2], and reduces the affinity of IL-23 for IL-23Rα through negative allosteric modulation[2]. |
| In vivo | Tildrakizumab (100 mg/kg, subcutaneous injection, every two weeks, up to 9 months) demonstrates good tolerability in cynomolgus monkeys (toxicity study)[3]. |
| Synonyms | SCH 900222, MK 3222 |
| Molecular Weight | 144.44 kDa |
| Cas No. | 1326244-10-3 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.